Stable corticosteroid compositions

A pharmaceutical composition comprising:

• budesonide;
• and
• ascorbate in an amount from about 0.05% to about 0.5% w/w of the composition;
• wherein the pharmaceutical composition has a pH of between about 4 and about 5.2, wherein the pharmaceutical composition has less than 0.3% 21 dehydrobudesonide (21 DHB).

A pharmaceutical composition comprising:

• a) budesonide in an amount of from about 0.001 to about 0.1% w/w of the composition;
• b) ascorbic acid and/or ascorbate in an amount of from about 0.05% to about 0.5% w/w of the composition;
• c) maltodextrin;
• d) disodium EDTA;
• e) citric acid;
• f) sodium citrate;
• g) Polysorbate 80;
• h) sodium benzoate;
• i) an optional flavoring agent, an optional sweetener, or combination thereof;
• or
• j) an aqueous liquid vehicle.

A pharmaceutical composition comprising:

• a) budesonide in an amount of from about 0.001 to about 0.1% w/w of the composition;
• b) a viscosity modifier in an amount of from about 0-10% w/w, wherein the viscosity modifier comprises carboxymethylcellulose, carbomer, HPMC, HEC, or a combination thereof;
• c) maltodextrin in an amount of from about 1 to about 50% w/w of the composition;
• d) disodium EDTA in an amount of from about 0.005 to about 1% w/w of the composition;
• e) citric acid in an amount of from about 0.01 to about 1% w/w of the composition;
• f) sodium citrate in an amount of from about 0.01 to about 1% w/w of the composition;
• g) Polysorbate 80 in an amount from about 0.001 to about 0.01% w/w of the composition;
• h) sodium benzoate in an amount from about 0 to about 1% w/w of the composition;
• i) ascorbate in an amount of from about 0.05% to about 0.5% w/w of the composition;
• j) a flavoring agent, sweetener, or combination thereof, and
• k) water;
• wherein the pharmaceutical composition comprises less than 0.3% impurities formed by oxidative degradation, and wherein the pharmaceutical composition is for oral administration.